key: cord-0868920-j9i7ffdb
authors: Mansoor, Emad; Perez, Abe; Abou-Saleh, Mohannad; Sclair, Seth N.; Cohen, Stanley; Cooper, Gregory S.; Mills, Alexandra; Schlick, Kayla; Khan, Ahmad
title: Clinical Characteristics, Hospitalization and Mortality Rates of COVID-19 Among Liver Transplant Patients in the United States: A Multi-Center Research Network Study
date: 2020-09-30
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.09.033
sha: b8e0957a22aaf9599c67e47bf0ad2295c2ec9943
doc_id: 868920
cord_uid: j9i7ffdb

nan

Liver transplant (LT) patients represent one of the largest immunosuppressed cohorts.

However, outcomes of COVID-19 in this population remain poorly defined although liver injury has been reported in patients with COVID-19 (1).

We sought to examine characteristics of LT patients infected with COVID-19 and study the rates of hospitalization, mortality, thrombosis, or ICU requirement in LT with COVID-19 in the US.

We used a large health research network (TriNetX) to compile electronic medical records (EMR) of adult (aged >18) LT recipients with confirmed SARS-CoV-2 infection (LT group), from 35 health care organizations (HCO) in US, from January 1, 2020 to June 23, 2020. Within this same time period, we also identified COVID-19 positive patients with no history of liver transplant (non-LT group). For both cohorts, we collected demographics, comorbidities, clinical symptoms and laboratory findings at COVID-19 diagnosis and presentation. To address confounders, cohorts were balanced using 1:1 greedy nearest-neighbor propensity score matching (PSM) based on age, race, and key comorbidities ( Table 1 ). The four outcomes of interest were risk of hospitalization (defined as composite outcome of inpatient or critical care services), mortality, thrombosis (defined as composite outcome of deep-vein thrombosis, acute pulmonary embolism, stroke, or myocardial infarction), and ICU requirement (requiring mechanical ventilation or ECMO) after a diagnosis of COVID-19. Further details on methodology are provided in the supplementary material.

Between January and June 2020, there were a total of 43,508 non-LT COVID-19 patients and 126 LT COVID-19 patients in the database (Table 1) . LT patients were significantly older, predominately male and white, and had higher prevalence of comorbidities (Table 1) . Thus, we performed (1:1) PSM for age, race and comorbidities. The LT and non-LT groups were relatively balanced after PSM (N=125 each group) ( Table 1) .

LT patients were more likely to have nausea and vomiting, malaise and fatigue, diarrhea, abdominal and pelvic pain. LT patients were more likely to have higher means levels of Cr, TBR and ALP (Table 1 ). Within 6 months prior to diagnosis of COVID-19, 39% of LT patients were receiving prednisone, 9% hydrocortisone, 61% tacrolimus, 37% mycophenolate motefil, and 8% each azathioprine, cyclosporine, sirolimus, everolimus and basiliximab (Supplementary Table 1 ).

Patients in the LT group had a significantly higher risk of hospitalization compared to the non-LT group, both before and after PSM (Table 1) . After PSM, in adjusted analysis, 40% of patients in the LT group required hospitalization compared to 23% of patients in the non-LT group (RR 1.72, p<0.0043). In unadjusted analyses, the risk of mortality (RR 2.27, p=0.0069), thrombosis (RR 3.55, p<0.0001) and ICU requirement (RR 2.64, p=0.0013) was higher in the LT group, however, after PSM there was no difference in risk of mortality, thrombosis and ICU requirement between LT and non-LT patients with COVID-19 (Table 1) .

We found LT patients with COVID-19 to have significantly higher risk of hospitalization, but not a higher risk of mortality, thrombosis or ICU requirement compared to patients without LT and COVID-19 upon adjusted analyses.

This is the largest study of LT patients with COVID-19 in the US to date. Yi SG et al. (3) reported 21 Solid Organ Transplant (SOT) recipients diagnosed with COVID-19 including 3 LT patients at a US high-volume transplant center. In this study, 33% (1/3) LT patients required hospitalization compared to 40% in our study and 33% (7/21) SOT patients required ICU care compared to 8% in our study.

Belli LS et al. (4) reported the European experience in 103 LT patients with COVID-19 from centers located in Italy, Spain, and France. While they found fever, cough, and shortness of breath to be most common presenting symptoms, we found LT patients to have a predominance of nausea and vomiting, malaise and fatigue, diarrhea, abdominal and pelvic pain. These differences in presenting symptoms might be due to differences in study design, methods of data collection, data analyses, and the size of source population. While 40% patients in our study were admitted to the hospital and 8% required ICU care, 81% of patients in their study required hospitalization and 15% were admitted to the ICU. Importantly, 16% of LT patients died in their study compared to a mortality rate of 8% in our study.

Our lower rate of hospitalization and ICU care requirements compared to the European, experience likely suggests earlier presentation and/or diagnosis in our patients. Furthermore, ICU requirement in our study was defined as requiring mechanical ventilation or ECMO, whereas in other studies the definitions were more liberal, thereby leading to a lower estimate of ICU requirement in our study. Other factors such as increased accessibility to a multidisciplinary post LT team and decreased threshold of admission for LT patients may also have played a role.

LT patients with COVID-19 had higher mean levels of Cr (2.03) suggestive of AKI compared to non-LT patients with COVID-19. Around 15-29% (5) of patients with has been reported to have elevated Cr. Although a significant proportion of LT patients were on J o u r n a l P r e -p r o o f calcineurin inhibitors, ACE2 expression in kidney is known to be nearly100-fold higher than in respiratory organs, and may increase risk of AKI in patients with COVID-19 (6).

In a recent Dutch study (7), on patients with COVID-19 pneumonia admitted to the ICU, 27% developed VTE and 3.7% developed arterial thrombotic events. In our study, the overall rate of thrombosis was 8%. The decreased rates of thrombosis in our study might be due to the differences in study population since the Dutch study included only patients with COVID-19 pneumonia admitted to the ICU who had severe disease leading to increased inflammatory burden. Ours is one of the very first studies in LT patients with COVID-19 to provide data on thrombosis, which appears to be reassuring. This study is limited by its retrospective nature and inaccessibility to treatment regimens, if any, for patients with COVID-19 and other information unavailable in the TriNetX database such as information about socioeconomic status, exposure history and geographic data of the patient population. In addition, data from EMR-based databases is susceptible to coding errors during translation of patient information into ICD-10 codes. However, TrinetX aggregates data from EMRs in real-time, which minimizes errors in data collection and analysis. Furthermore, patients with mild disease who were undiagnosed and did not present to HCOs were not captured in our study and thus our cohort likely represents a relatively severe spectrum of COVID-19.

However, compared to prior studies on LT and COVID-19, our estimate of hospitalization and mortality rates in LT might be more precise given our higher sample size in both LT and non-LT groups with COVID-19.

In conclusion, in one of the largest multi-center network studies on LT and COVID-19 to date, we found LT patients with COVID-19 to have significantly higher risk of hospitalization J o u r n a l P r e -p r o o f but not mortality, thrombosis, or ICU requirement compared to patients without LT and COVID-19, when matched for severity of illness. Given the limitations and retrospective nature of this study, further prospective studies are needed to evaluate the burden of care in LT patients and long-term outcomes of LT patients with COVID-19. 

Liver injury in COVID-19: management and challenges

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume

COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Kidney disease is associated with in-hospital death of patients with COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19